Epigenetic Research & Inflammatory Disease Applications: High-Purity Chromatin Reagents and Assay Development Tools
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for H4C2-centered epigenetic and inflammation research. Select your research modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Native Antigen | H4C2 Recombinant Histone H4 Protein; High purity (>95%), Sequence Verified, Endotoxin <1EU/μg. Suitable for nucleosome assembly. | View H4C2 Products |
| Modified Antigen | H4C2 PTM Variants (H4K20me3, H4Ac); Site-specifically modified, Mass Spec verified. For reader/writer enzyme assays. | View H4C2 Products |
| Gene Delivery | H4C2 Premade Lentivirus / Promise-ORF; Full-length ORF with N-terminal FLAG tag for stable cell line generation. | View H4C2 Products |
| Detection / Benchmark Ab | Anti-H4C2 Monoclonal Antibody; Recombinant rabbit mAb, validated for ChIP and Western Blot. | View H4C2 Products |
| Functional Validation (siRNA) | H4C2 siRNA Set (3 unique sequences); For knockdown and specificity verification in chromatin assays. | View H4C2 Products |
| Epigenetic Writer | DOT1L (H3K79 Methyltransferase); Enzyme for histone modification assays. | View DOT1L Products |
| Epigenetic Eraser | HDAC1 (Histone Deacetylase); Key enzyme for H4 deacetylation studies. | View HDAC1 Products |
| Epigenetic Reader | BRD4 (Bromodomain-containing Protein); H4 acetylation mark reader protein. | View BRD4 Products |
| Related Target A | EZH2; Epigenetic writer interacting with histone modifications. | View EZH2 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Enzymatic Assay Interference | High Purity (>95%) strictly verified, avoiding off-target epigenetic modifications. |
| Isoform Homology Screening | Sequence Verified proteins ensuring exact histone cluster 2 sequence fidelity. |
| Nucleosome Assembly Complexity | Octamer-quality H4C2 protein with verified folding; compatible with H2A/H2B/H3 refolding protocols. |
| PTM Site Specificity | Homogeneous modifications (mono/di/tri-methyl lysine 20) validated by high-resolution mass spectrometry. |
| Extracellular vs Nuclear Detection | Conformation-specific antibodies distinguishing soluble H4 from chromatin-bound forms. |
| Cross-Reactivity with H4 Variants | Sequence alignment verified against H4F/H4H isoforms; >99% identity coverage. |
| Lack of Controls | Clinical Benchmark Antibodies included. |
| False Positives | Validated siRNA included for specificity checks. |
Live H4C2 R&D Tracker
Access the latest global research on histone H4 in epigenetics and inflammatory diseases:
- ➤ View Active Clinical Trials for H4C2
- ➤ View Active Inflammation Trials
- ➤ Latest Extracellular Histone Research
- ➤ H4K20 Methylation & Cancer Studies
- ➤ Latest Resistance Research
- ➤ Recent Patent Filings
Global Research Landscape & Therapeutic Outlook
The targeting of H4C2 (Histone H4) represents a dual-frontier opportunity in modern drug discovery: (1) as a substrate for epigenetic enzyme inhibitors targeting writers/erasers of H4 post-translational modifications, and (2) as a Damage-Associated Molecular Pattern (DAMP) in acute inflammatory conditions where extracellular histone H4 drives toxicity. The race for H4C2-relevant therapeutics is intensifying, with major players shifting focus from traditional generic inhibitors to targeted epigenetic modulators (e.g., Epizyme, Constellation) and antibody-mediated neutralization of circulating histone H4 for sepsis and acute lung injury. As first-generation therapies reach the clinic, the next wave targets highly specific reader/writer complexes and overcomes acquired resistance in solid tumors and hematological malignancies. Current R&D focuses heavily on biochemical assays for methyltransferase and deacetylase inhibitor screening using highly purified, site-specifically modified H4 substrates, alongside advancing neutralizing antibody programs for inflammation.
Competitive Modality & Application Snapshot
| Modality | Research Focus / Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|
| Neutralizing mAb | Extracellular H4 DAMPs (Sepsis, ARDS, Autoimmunity) | Native unmodified H4 protein for binding assays |
| Small Molecule Inhibitors | Epigenetic enzymes (Oncology, e.g. H4K20me loss) | Modified H4 substrates (H4K20me3, H4Ac) for high-throughput screening |
| PROTACs | Chromatin readers (Refractory Solid Tumors) | Full-length nucleosome substrates with specific PTMs |
| siRNA/Antisense | Rare genetic disorders | Specific siRNA sets for knockdown validation |
| Biochemical Tools | Nucleosome assembly (Mechanistic Biology) | High-purity tetramer/octamer components |